Subscribe To

Price Alert Latest News Economic Calendar News

ALKS / Alkermes plc (ALKS) Q4 2022 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Todd Nichols - Chief Commercial Officer Iain Brown - Chief Financial Officer Richard Pops - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Akash Tiwari - Jeffries Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs Paul Matteis - Stifel Uy Ear - Mizuho Jason Gerberry - Bank of America Jessica Fye - J.P. Morgan Marc Goodman - SVB Douglas Tsao - H.C. Read More

Demo Live Account See Partner Details

Content Topics

Alkermes

ALKS

2022

Earnings

Call

Transcript

alks

Stock

Posted: Feb 16 2023, 11:46

Author Name: Seeking Alpha

ALKS News

By Zacks Investment Research
October 26, 2023

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023.

By The Motley Fool
October 25, 2023

Why Alkermes Stock Is Sinking Today

Alkermes' third-quarter results beat Wall Street's expectations. However, investors appeared to still be disappointed with a clinical update announced

By Investors Business Daily
October 23, 2023

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.

Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment.

By Zacks Investment Research
September 7, 2023

Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average

Alkermes (ALKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALKS broke through

By Zacks Investment Research
August 31, 2023

Alkermes (ALKS) Grants Teva License to Market Generic Drug

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. Th

By Market Watch
August 30, 2023

Alkermes shares surge after settlement with Teva on alcohol dependence treatment

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Tev

By Seeking Alpha
August 24, 2023

Lybalvi: Weighing In Light, But Tipping Alkermes' Scales

Alkermes to split neuroscience and oncology divisions; strong growth with drug Lybalvi highlighted. Financials show robust growth; concerns include a

By Seeking Alpha
July 26, 2023

Alkermes plc (ALKS) Q2 2023 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS ) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Cor

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.